145 results on '"Nieto-Jiménez, Cristina"'
Search Results
2. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
3. Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D
4. Clinical considerations for the design of PROTACs in cancer
5. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies
6. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2
7. MZ1 co-operates with trastuzumab in HER2 positive breast cancer
8. Mapping immune correlates and surfaceome genes in BRAF mutated colorectal cancers
9. Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
10. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities
11. Genomic expression of MSR1 in solid tumors associates with response to anti-PD1 and anti-CTLA4 therapies
12. Data from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
13. Figure S3 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
14. Legends to Supplementary Material from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
15. Table S1 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
16. Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
17. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
18. Antitumoral activity of a CDK9 PROTAC compound in HER2-Positive breast cancer
19. Additional file 1 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
20. Additional file 2 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
21. Additional file 4 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
22. Additional file 7 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
23. Additional file 8 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
24. Additional file 3 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
25. Additional file 5 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
26. Additional file 6 of MZ1 co-operates with trastuzumab in HER2 positive breast cancer
27. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
28. MZ1 co-operates with trastuzumab in HER2 positive breast cancer
29. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
30. Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
31. Pan-BCL2 family inhibitor obatoclax as treatment for parental and cisplatin-resistant triple negative breast cancer
32. Evaluación de la inhibición farmacológica de nuevas dianas terapéuticas identificadas en el cáncer de mama triple negativo
33. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
34. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
35. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
36. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
37. Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
38. Mapping Bromodomains in breast cancer and association with clinical outcome
39. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
40. Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
41. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
42. Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
43. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
44. Mapping Bromodomains in breast cancer and association with clinical outcome
45. Epigenetic mutational landscape in breast cancer: role of the histone methyltransferase gene KMT2D in triple negative tumors
46. Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
47. Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
48. Mapping Bromodomains in Breast Cancer and Its Association with Clinical Outcome
49. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
50. DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.